This paper develops hypotheses regarding the interactions among stress, immunity, and chemical sensitivities and gives an overview of the questions and hypotheses generated by a working group exploring the application of psychoneuroimmunology to chemical sensitivities. Consideration is given to prospective longitudinal studies designed to find cases among at-risk exposed populations. Relevant immune parameters to be measured longitudinally and in challenge studies for patients with MCS are discussed. Immune system changes in response to the chronic stress of having MCS and as primary responses to chemical exposure also are considered. Environ Health Perspect 1 05(Suppl 2): 527-529 (1997) 
Introduction
Psychoneuroimmunology is defined as the study of behaviorally associated changes in immunity and immunologically associated changes in behavior that result from the interaction among the nervous, endocrine, and immune systems (1, 2) . The charge to this working group was to develop experimental protocols with which to investigate multiple chemical sensitivity (MCS) from the heretofore unconsidered perspective of psychoneuroimmunology. Given that the involvement of the immune system in MCS is still an area of some controversy, the impact of psychoneuroimmunological processes on the onset, development, and dinical course of MCS is problematic. Thus, the group also considered a reasonable area of scientific inquiry to be the possible influences on immunity of the stress associated with MCS as a chronic disability (3).
Experimental Questions Relevant to the Relationship between Exposure and Symptoms in Chemical Sensitivities
During its deliberations, the group raised the following six related sets of questions whose answers could reveal a relationship among behavioral stimuli, neural-immune system interactions, and MCS.
In situations in which a sensitizing chemical may be immunomodulatory, do environmental cues temporally associated with the sensitizing exposure serve as conditioned stimuli (4 behavioral mechanisms. The second hypothesis states that the stress associated with MCS as a chronic disabling disease leads to an altered neuroendocrine immune milieu which, in turn, is associated with measurable changes in immune function and associated incidence and severity of immunologically related diseases (e.g., infectious disease, autoimmune disease, cancer). Both of these hypotheses are testable in prospective longitudinal studies involving the following populations. Study 1: Population exposed to a chemical initiating event-for example, the installation of new carpets (including glue) in the workplace. Study 2: Population exposed to a manmade chemical spill. Study 3: Population exposed to a natural disaster such as an earthquake, flood, or hurricane.
Subject Selection
An assumption common to each study population is that some percentage of the individuals in each heterogeneous population will within a predetermined period (e.g., 1 year) develop MCS. These subjects will comprise the first study group. A second group will consist of those individuals who have been exposed to the same stimuli but do not develop MCS within the same predetermined time period. To determine whether individuals in this second group exhibit any immunological consequences of the exposure that might have a psychosocial attribution, a group of demographically matched individuals that have not been exposed could be studied. Given the assumption that the cost of performing these studies is of no consequence, all subjects in each study population will be evaluated, by health status, by a full battery of immunological tests. Some examples of immunologic assessments are serum immunoglobulin levels (all isotypes); complement levels; mitogen responses; TH1and TH2-derived cytokine levels; proinflammatory cytokine (e.g., IL-1, IL-6, TNF-a) levels; soluble and cell-bound cytokine receptors; natural killer (NK) cell numbers and activity; substance P and proinflammatory cytokines in nasal lavage; quantitative cytokine mRNA; antibody titers to volatile organic compounds (VOCs); antibodies to a benign antigen or flu vaccine (immunized during study); and skin testing with standard recall antigens and allergens. Psychometric instruments will also be used to evaluate such factors as stress, loneliness, coping, helplessness, and suggestibility. The following are examples of psychometric instruments: the Profile of Mood States questionnaire; the Minnesota Multiphasic Personality Inventory; the Reaction Scheme Test; and the State and Trait Anxiety Inventory. These procedures will be done before and periodically after (e.g., 1, 3, 6, 9, 12 months) the putative initiating event. Variables to be considered (and controlled for) as ways of separating (stratifying) the subject population, include but are not restricted to the typical demographic issues of age, sex, socioeconomic status, and ethnicity. The hypothesis to be tested is that: some psychosocial factor(s) will distinguish individuals who develop MCS from those who do not.
Total VOC concentration and selected VOCs will be measured in the air and biological fluids (blood) of the subjects to determine the actual exposure received in study 1. Estimates of the exposures in study 2 would rely on measurements in biological fluid (blood or urine) of the suspected compounds of exposure or their metabolites. Consideration must be given to the time interval between when the exposure occurred and when the biological sample was collected and the biological half-life of the species measured.
Controlied Exposure Studies
There are multiple design problems inherent in conducting clinical studies of MCS patients under controlled exposure conditions. These include selection of the appropriate exposure conditions such as routes of delivery, issues regarding blinding or masking, and identification and utilization of relevant response measures. With respect to relevant response measures, most MCS patients report acute symptoms that occur within minutes to hours of the exposure. The time course of this symptomexposure relationship makes mechanisms involving neoantibody production highly suspect and focuses attention on local inflammatory responses; the production/ release of proinflammatory cytokines such as IL-1, IL-6, and TNF-a; the release of acute phase proteins; and immediate hypersensitivity reactions.
One design problem associated with these studies is selecting the time after the initiating event when individuals who develop MCS in the study populations should undergo controlled exposure testing. This could be a fixed time (e.g., 1 year) after the initiating event or it could be a predetermined time after development of MCS that is independent of the time of the initiating event. If the latter time is used, then selection of the individual from the exposed group who does not develop MCS at the time of a controlled exposure becomes a problem (i.e., that individual could, in principle, still develop MCS after the predetermined time).
There are several approaches to performing controlled exposure studies that may be applicable to the MCS question. Perhaps the most valid approach to controlled subject testing is a double-blind study design in which the subject is unable, from usual sensory perceptions, to detect the exposure condition. If the controlled exposure is conducted within a longitudinal study as described, it would be useful to compare the psychosocial variables collected at initiation of the studies for those subjects with high and low hit rates for detecting chemicals in subthreshold concentrations.
Although olfactory maskers were successfully used in one study, the odors and irritant effects of volatile organic chemicals make blinding extremely difficult. One can consider using subthreshold exposure levels where individual subject perceptual (olfactory, sensory irritation) thresholds are determined and exposure conditions are set at some magnitude below this level. However, in considering the complexities and controversies of MCS, such studies likely would come under intense criticism if performed without allowing for the adaptation/masking phenomena described by MCS proponents. Another approach in reevaluating the MCS phenomenon is to utilize above-threshold exposures in an attempt to identify physiological or biochemical parameters that provide biologic plausibility for the reported symptoms; such work would be exploratory. Using recognizable above-threshold exposures would not be blinded and would not differentiate between conditioning and other underlying mechanisms. However, such an approach possibly would provide a measure other than symptoms that could then be examined further with regard to dose-response, routes of exposure, and blinding. This approach would require studying subjects who report the symptoms of interest.
Response Measures
In addition to measuring symptoms of MCS, preference should be given to measures that can be made during or in close proximity to exposures. The measures selected must have biologic plausibility for the symptoms reported by the MCS
patients. Most MCS patients report acute
Environmental Health Perspectives * Vol 105, Supplement 2 * March 1997 symptoms that occur within minutes to hours following an exposure. The time course of this symptom-exposure relationship makes mechanisms that involve antibody production or cell-mediated immunity highly suspect and focuses attention on local (e.g., nasal) inflammatory responses and the local and systemic production of proinflammatory cytokines such as IL-1, IL-6 and TNF-a measured preand postexposure. Additional analyses of endocrine activation (stress hormones such as salivary cortisol) and autonomic nervous system arousal (heart rate, skin conductance, pupilography, catecholamines) before and after deliberate exposure should also be conducted. In summary, the following should be examined during or in close proximity to challenges: systemic inflammatory markers (e.g., proinflammatory cytokines) (relevant symptoms: fatigue, arthralgias, myalgias); nasal inflammatory markers-neuropeptides, proinflammatory cytokines, histamine/tryptase, cells, albumin (relevant symptoms: nasal symptoms); autonomic nervous system-heart rate, skin conductance, pupilography (relevant symptoms: dizziness, palpitations, flushing, cold extremities, anxiety); endocrine system-stress hormones (e.g., salivary cortisol, prolactin); stress measures-heart rate, respiratory rate, end-tidal CO2 (relevant symptoms: anxiety, palpitations, dyspnea).
Psychoneuroimmunological Consequences ofMCS
Regardless of whether there is a psychoneuroimmunological component to the development of MCS, it is reasonable to hypothesize that there are behavioral and immunological consequences of MCS that may be attributable to the stress of a chronic disability (3). Thus, it might prove useful to longitudinally follow individuals who develop MCS and periodically monitor their psychosocial status, immune function, and general health. An important related question, at least from the perspective of the psychoneuroimmunologist, is whether abnormalities in any of these parameters are associated, at least correlationally, with an altered incidence of microbial diseases, autoimmune diseases, and cancer. If so, perhaps appropriate psychosocial interventions can be developed. In terms of intervention, it would be informative to determine the extent to which MCS patients are consumers of alternative (complementary) medical therapies, and whether such treatments have beneficial effects.
